An observation on curative effect of continuous intravenous injection of Shengmai injection for treatment of patients with acute coronary syndrome combined with cardiogenic shock
10.3969/j.issn.1008-9691.2013.05.009
- VernacularTitle:持续生脉注射液静脉注射治疗急性冠脉综合征合并心源性休克的疗效观察
- Author:
Jingbai DU
;
Junjiang LI
;
Ying XU
;
Zengjun HU
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Cardiogenic shock;
Shengmai injection;
Integretion of traditional Chinese medicine and western medicine
- From:
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
2013;(5):283-285
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of continuous intravenous pump of Shengmai injection for treatment of patients with acute coronary syndrome(ACS)combined with cardiogenic shock. Methods In the period from January 2005 to March 2011,33 hospitalized patients with ACS complicated by cardiogenic shock were selected in the treatment group,and in the same period,32 in-patients with ACS were enrolled in the control group, According to traditional Chinese medicine(TCM)syndrome type,the treatment group was subdivided into Yin xutype(Yin deficiency,15 cases),Qi xu type(Qi deficiency,11 cases),Xue yu type(blood stasis,7 cases). Conventional western medicine treatment was given to the two groups,besides,Shengmai injection in 30-60 mL intravenous drip,once a day was applied in the control group,while in the treatment group,Shengmai injection in 10-100 mL/h trace pump continuous intravenous infusion was given,after the blood pressure returned to normal,the infusion was changed to 5 mL/h trace pump continuous intravenous injection for consecutive 5-7 days. After treatment, the changes of clinical efficacy,blood pressure,heart rate ,improvement of clinical symptoms were observed in two groups,and the changes of mean arterial pressure(MAP)in cases with different syndromes in treatment group were also investigated. Results The rates of the significant therapeutic effect and total effect in the treatment group were obviously higher than those in the control group〔significant effect:69.7%(23 cases)vs. 46.9%(15 cases);the total efficacy:90.9%(30 cases)vs. 62.5%(20 cases),both P<0.05〕. The comparisons of blood pressure and heart rate before and after treatment in the two groups were not significant(all P>0.05). After 48 hours of treatment in the two groups,the clinical symptoms were all improved〔chest pain:2 cases(6.1%)vs. 10 cases(31.3%),sweating:3 cases(9.1%)vs. 13 cases(40.6%),shortness of breath:4 cases(12.1%)vs. 12 cases(37.5%),all P<0.05;heart palpitations:5 cases(15.2%)vs. 9 cases(28.1%),nausea:3 cases(9.1%)vs. 4 cases(12.5%),both P>0.05〕. In treatment group,the increase of MAP in patients withYin xutype(mm Hg,1 mm Hg=0.133 kPa)was higher than that in patients with Qi xu type and Xue xu type(105.00±8.53 vs. 91.00±9.53,89.00±3.53,both P<0.05). Conclusion Continuous intravenous injection of Shengmai injection has significant therapeutic effect for treatment of patients with ACS combined with cardiogenic shock.
